Filed Pursuant to Rule 433

Registration Statement No. 333-251992

Issuer Free Writing Prospectus dated January 11, 2021

Relating to Preliminary Prospectus dated January 8, 2021

Nasdaq: LTRN 1 Lantern Pharma Company Overview January 11, 2021 Leveraging A.I., Machine Learning & Genomics to Rescue, Repurpose and Develop Targeted Cancer Therapies Filed Pursuant to Rule 433 Registration Statement No. 333 - 251992 Issuer Free Writing Prospectus dated January 11, 2021 Relating to Preliminary Prospectus dated January 8, 2021

Nasdaq: LTRN 2 SPECIAL NOTE REGARDING FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended . These forward - looking statements include, among other things, statements relating to : future events or our future financial performance ; the potential advantages of our RADR ® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate ; our strategic plans to advance the development of our drug candidates ; estimates regarding the development timing for our drug candidates ; our strategic plans to expand the number of data points that our RADR ® platform can access and analyze ; our research and development efforts of our internal drug discovery programs and the utilization of our RADR ® platform to streamline the drug development process ; our intention to leverage artificial intelligence, machine learning and genomic data to streamline the drug development process and to identify patient populations that would likely respond to a drug candidate ; estimates regarding potential markets and potential market sizes ; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others . Any statements that are not statements of historical fact (including, without limitation, statements to the effect that Lantern Pharma Inc . or our management "believes", "expects", "anticipates", "estimates", "plans", and words such as “targets,” “objectives” (and similar expressions) should be considered forward - looking statements . There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward - looking statements such as the impact of the COVID - 19 pandemic, the results of our clinical trials, and the impact of competition . Additional factors can be found in the Risk Factors section in our preliminary prospectus, dated January 8 , 2021 , on file with the Securities and Exchange Commission . You may access our January 8 , 2021 preliminary prospectus under the investor SEC filings tab of our website at www . lanternpharma . com or on the SEC's website at www . sec . gov . Given these risks and uncertainties, we can give no assurances that our forward - looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward - looking statements will in fact occur, and we caution investors not to place undue reliance on these statements . Furthermore, we operate in a competitive and rapidly changing environment . New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward - looking statements contained in this presentation . You should read this presentation, the preliminary prospectus we have filed with the SEC and the documents we reference in the preliminary prospectus and have filed as exhibits to the registration statement of which the preliminary prospectus is a part completely and with the understanding that our actual future results may be materially different from what we expect . All forward - looking statements in this presentation represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward - looking statements to conform the statement to actual results or changes in our expectations .

Nasdaq: LTRN 3 FREE WRITING PROSPECTUS • We have filed a registration statement (including a prospectus) with the SEC for the offering to which this communication rel ate s. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about us a nd this offering. You may get these documents for free by visiting EDGAR on the SEC website, www.sec.gov . Alternatively, we, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you contact ThinkEquity , a division of Fordham Financial Management, Inc., located at 17 State Street, 22 nd Floor, New York, NY 10004, by telephone at (877) 436 - 3673 or by email at prospectus@think - equity.com . • All investors viewing these materials should first access the prospectus by clicking on the following link: https://www.sec.gov/Archives/edgar/data/1763950/000121390020011747/0001213900 - 20 - 011747 - index.htm MARKET AND INDUSTRY DATA • This presentation and the preliminary prospectus made available to you herewith contains estimates, projections and other inf orm ation concerning our industry, our business and the markets for our drug candidates, including data regarding the estimated size of such markets and the incidence of certain med ica l conditions. We obtained the industry, market and similar data set forth in this presentation and the preliminary prospectus from our internal estimates and research and from aca demic and industry research, publications, surveys and studies conducted by third parties, including governmental agencies. In some cases, we do not expressly refer to the sources fro m which this data is derived. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and act ual events or circumstances may differ materially from events and circumstances that are assumed in this information. While we believe our internal research is reliable, such resea rch has not been verified by any third party. • This presentation highlights basic information about us and the offering. Because it is a summary, it does not contain all of th e information that you should consider before investing. This offering may only be made by means of the prospectus. Except as otherwise indicated, this presentation spea ks only as of the date hereof. • This presentation does not constitute an offer to sell, nor a solicitation of an offer to buy, any securities by any person i n a ny jurisdiction in which it is unlawful for such person to make such an offering or solicitation. Neither the Securities and Exchange Commission (the ”SEC”) nor any other regulatory body ha s a pproved or disapproved of our securities or passed upon the accuracy or adequacy of this presentation. Any representation to the contrary is a criminal offense. https://www.sec.gov/Archives/edgar/data/1763950/000121390021001239/ea132545 - s1_lanternpharm.htm

Nasdaq: LTRN 4 Drugs that have failed clinical trials or have been abandoned by pharma and biotech companies in late stage trials • Big data (genomic, clinical, response) assembled and analyzed • Patient subgroups identified through machine learning and artificial intelligence • Mechanisms of action clarified • Potential combinations identified • Potential for faster and more efficient path to relaunching in the clinical trial setting • Patient stratification based on A.I. enabled genomic biomarker discovery • New patient populations for failed or abandoned drugs based on validated biomarker signatures • Aimed to shorten time to market • Designed to reduce risk in development • Potential for orphan or fast track status • New Chemical Entities designed and filed Failed or Abandoned Drug Assets RADR ® Responders Non - Responders Lantern leverages A.I. to rescue and develop cancer therapies and has the potential to transform the cost, risk and timeline of drug development

Nasdaq: LTRN 5 Current oncology drug development is costly, risky, and inefficient … a perfect problem area for artificial intelligence & machine learning 3.3% (1) Avg. success rate of oncology drugs $2.8B (2) R&D investment to bring new cancer drug to market 2009 - 2018 17,000+ Oncology trials conducted from 2001 - 2015 2X Success rate of oncology trials using biomarker Note 1: https://globalforum.diaglobal.org/issue/may - 2019/what - are - the - chances - of - getting - a - cancer - drug - approved/ Note 2: https://www.biopharmadive.com/news/new - drug - cost - research - development - market - jama - study/573381/ Source: Wong CH et al.. Biostatistics (2018) Challenges in drug development … …are being met by data - driven, and A.I. approaches

Nasdaq: LTRN 6 1. “... low efficacies of cancer drugs might be attributed to the heterogeneity of the tested patient population , which essentially dilutes the strong therapeutic effect that a drug might have on a specific patient subgroup .” Thiebault Geoux , Ph.D. Chemistry - Elsevier 11/9/2015 10.1 7.6 7.3 4.8 5.5 4.2 4.2 3.7 1.9 1.8 0 2 4 6 8 10 12 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 R&D ROI Source: Deloitte research, 2019 Absolute Internal Rate of Return (IRR, %) There is a critical need to rescue drugs that failed or bring abandoned therapeutic assets to market in order to create ROI for biopharma 2. “The ever - increasing catalog of genetic changes involved in cancer development is fueling a new generation of targeted drugs that are designed to address specific weaknesses in tumor cells . But these drugs will only work in a subset of patients – creating a demand for genetic stratification . Allison Halliday, Ph.D. Cancer Research, 01/31/2020 Cancer Biomarkers: Powering Precision Medicine ROI Among The Top 12 Pharma – Continuous Decade of Decrease • Our A.I. platform helps to solve these two central problems in oncology drug development with unprecedented speed and cost • This allows us to increase the potential for success and improve trial design

Nasdaq: LTRN 7 Scalable, Unique Artificial Intelligence Platform – RADR® • 1+ Billion datapoints covering over 140+ drug/tumor interactions • Validated in multiple case studies with over 80%+ blinded accuracy • Integration of real - world, patient data from thousands of patients • Active collaboration with NCI in oncology therapeutics • Use of genomic, transcriptomic, clinical and drug sensitivity data • Guides development of patient stratification and CDx strategy • Published posters and studies at ASCO and AACR (2018, 2019, 2020) • Helped drive first out - licensing deal for LP - 100 • Helped identify ADC program for potential development 1. Guided the genetic signature to determine patient response for LP - 100 which was out - licensed within one year 2. Expanded LP - 100 for use in cancers that have a DNA damage repair gene mutation (ERCC 2,3) 3. Uncovered potential mechanisms of action for LP - 300 – which has shown notable and statistically significant results in prior trials, (with certain patient populations) but failed to meet broader endpoints 4. Highlighted potential pathways and genes involved in both the response to LP - 184 and the biological mechanisms that are involved in activity across multiple tumors 5. Identified potential new candidates for rescue, repurposing and in - licensing – including ADC combinations Rapidly Accelerating Our Portfolio Value Lantern’s focus on oncology, and advancing the portfolio where we own the therapeutic rights makes us uniquely positioned and differentiated

Nasdaq: LTRN 8 x Has identified several indications for new, genomically validated programs for LP - 184 x Provided insights and targets for pursuit using an ADC approach x Scaled 4x+ since IPO, plan an increase of 3x to 5x during 2021 calendar year x Potential to significantly reduce the complexity, cost and timeline associated with drug development Unique Portfolio of Clinical Stage Targeted Cancer Therapeutics High - Performance, Rapidly Growing A.I. Platform Major pillars of shareholder and patient value at Lantern Pharma Novel Highly Potent ADC Program x Programs in Phase 2 in targeted cancer indications x Unique, patented small molecules being developed with biomarker signatures x Phase 2 in mCRPC (prostate) x Phase 2 (mid 2021) in NSCLC (lung) x Targeted indications in GBM, Pancreatic and other solid tumors x Targeting novel programs with patented compounds and unique linker technologies x Optimized for portfolio of Lantern’s DNA damaging compounds x Leveraged RADR to identify ideal targets and cancers that can benefit from the combination x Ability to partner early with pharma based on market and technology demand for ADC programs

Nasdaq: LTRN 9 Types of data: • Complete transcriptome data • RNA gene expression data • Drug sensitivity data • DNA copy number and mutation data • Clinical stage of tumor /cancer • Histology of tumor • Patient age , sex , race and ethnicity • Prior treatment history and response * Historical datapoints are approximate and based on end of year analysis ** Future datapoints are based on Company’s product development plans DATAPOINTS POWERING RADR ® Patient Value Clinical Value 10 Billion > 2022** 3 - 5 Billion > 2021** 1 Billion > 2020* 125 Million > 2019* 10 Million > 2018* Sources of data: • Clinical history of the drug • Published research (e.g., ASCO, journals) • Proprietary sequencing studies • Partnerships/Collaborations • Public sources (e.g., NCI) Extensively Curated & Scored

Nasdaq: LTRN 10 Lantern’s Unique & Rapidly Developing Pipeline Accelerated Development by Leveraging the RADR ® A.I. platform 80+ issued patents and pending applications across 14 patent families Phase I Phase II LP - 184 LP - 100 (Irofulven) LP - 300 Drug Preclinical Indication Prostate Cancer Successfully partnered & out - licensed Non - Small Cell Lung Cancer (Focused on Never - Smokers) Solid Tumors (Location agnostic tumors identified by RADR® defined genomic signature) Phase III R&D Glioblastoma (Responsiveness predicted by RADR® and confirmed in wet - lab studies) LP - 184 Targeting a sub - population in NSCLC of Adenocarcinoma subtype Development Collaborations With: • Johns Hopkins School of Medicine Development Collaborations With: • Georgetown University • Fox Chase Cancer Center ADC Programs Select Solid Tumors Leveraging novel linker library & with unique DNA - damaging agents with proven antibodies

Nasdaq: LTRN 11 Nearly 1 M patients annually worldwide with several Billion $USD in potential future oncology therapy sales Prostate Cancer Non - Small Cell Lung Cancer (NSCLC) Ovarian, Pancreatic & Liver Cancer 1.3 million 2018 Estimated Global Incidence 208,000 2018 Estimated G lobal metastatic hormone - resistant prostate cancer subpopulation 2 million 2018 Estimated Global Incidence 240,000+ 2018 Estimated Global never - smoker NSCLC adenocarcinoma subpopulation 1.6 million 2018 Estimated Combined Global Incidence 400,000 2018 Estimated Global cancer subpopulation non - responsive to or relapsed after chemotherapy and with potential biomarker signature for response Glioblastoma (GBM) 11,000 - 13,000 2019 estimated GBM Cases in the USA 240,000+ 2018 Estimate of new GBM cases globally 3 Drug Candidates in Development in Targeted Patient Segments With Clinical Need Sources: American Cancer Society, Global Database, AANS, NCI, Lantern Pharma meta analysis

Nasdaq: LTRN 12 Overview of Lantern’s Small Molecule Portfolio LP - 100, Irofulven LP - 184 LP - 300 • DNA Damaging Agent • Mediates cytotoxicity through multiple mechanisms such as DNA adduct formation, RNA polymerase stalling and redox protein modification • Use in a precision medicine, genomic - signature guided Phase II trial (NCT03643107) for metastatic, castration - resistant prostate cancer ( mCRPC ) • Expansion into cancers with ERCC2/ERCC3 mutations (both germline and inherited) • Novel DNA Damaging Agent - member of the acylfulvene prodrug class • Favorable in vitro and in vivo efficacy across multiple tumor types • Broad anti - tumor agent that counteracts multi - drug resistance • Nanomolar potency • A.I. generated, validated and published gene signature for solid tumors • Key payload for ADC programs • Disulfide bond disrupting agent with cysteine modifying activity on select proteins (ALK) and modulator of protein function (EGFR, MET, ROS1) • Chemosensitizer for combination therapies by inactivating proteins modulating cell redox status and drug resistance (TRX, GRX, PRX) • Chemoprotectant activity that reduces toxicities associated with taxane / platin - based chemotherapies

Nasdaq: LTRN 13 LP - 100 ( Irofulven ): Historical* phase II trial results in prostate cancer *Historical data from Hart et al., Randomized phase II trial of irofulven /prednisone, irofulven /capecitabine/prednisone, or mitoxantrone/prednisone in hormone refractory prostate cancer (HRPC) patients failing first - line docetaxel. European Journal of Cancer Supplements (2006) 41 22 0 10 20 30 40 50 1 Year Survival % Median Overall Survival After 12 Months Irofulven Control (Mitoxantrone) Median 1 yr. survival was 86% greater in Irofulven in combination treated metastatic prostate cancer patients v. control • Out - licensed to Allarity Therapeutics in 2016 • Patients screened using Irofulven - specific biomarker signature and eligible patients recruited with Hormone Refractory Prostate Cancer (HRPC) • Allarity Therapeutics dosed first patient in HRPC in Q4 2018 in a Phase 2 trial using biomarker technology to ID and monitor patients • Trial design estimates up to 27 patients to be enrolled • Lantern Pharma can receive up to $14M or a specified percentage of future earnings from the sale or out - licensing of LP - 100 • First patient dosed in mHRPC (metastatic, hormone - resistant prostate cancer) in Q4 2018 in a Phase II trial using biomarker screening technology on the tumor to select patients • US patent directed to use of drug in combination with tumor biomarker signature ( filed by Allarity Therapeutics ) through 2036 Precision Phase II Trial LP - 100

Nasdaq: LTRN 14 LP - 300 in development for never - smokers with NSCLC adenocarcinoma based on strong historical data & biomarker studies Mechanism of action • Disulfide bond disrupting agent • Disrupts by covalently modifying cysteine • Inhibits and modulates activity of proteins in NSCLC pathways (ALK, EGFR, MET, ROS1) • Targeting never - smoker sub - population, as a potential target rare disease market (est. start mid - 2021) • Designing phase II clinical trial for use in non - smokers with NSCLC adenocarcinoma • Exploring preclinical in vivo studies to characterize efficacy as a combination with approved targeted therapies • Leveraging RADR ® to develop biomarker signature that can be used to predict patients most likely to respond to combination therapy with LP - 300 Current status Prior Clinical Experience • Prior history in 5 phase 1 and 5 phase 2 and 3 clinical trials in lung and breast cancers as a combination agent • LP - 300 has been administered to over 1,000 patients and has been generally well tolerated • Prior studies did not stratify or select patients based on biomarker or smoking status LP - 300

Nasdaq: LTRN 15 Source: Phase 3 clinical trial, study ID DMS32212R, conducted by BioNumerik Pharmaceuticals - subpopulations receiving paclitaxel/cisplatin 30% 51% 63% 72% 25% 31% 28% 32% All patients Females never-Smokers Female never-Smokers 2 Year Survival % LP-300 + Cisplatin/ Paclitaxel Placebo + Cisplatin/ Paclitaxel 20% increase in 2 Year Survival Compared to Placebo 125% increase in 2 Year Survival Compared to Placebo 65% increase in 2 Year Survival Compared to Placebo 125% increase in 2 Year Survival Compared to Placebo (N=114) (N=87) (N=66) (N=288) Lantern’s precision oncology approach in the LP - 300 Phase II trial will build on a prior Phase III trial that did not meet clinical efficacy endpoints but demonstrated survival benefit in a patient subgroup LP - 300

Nasdaq: LTRN 16 All never - smokers N = 87, HR = 0.519 (p value 0.0462) Survival months Survival probability 0 10 20 30 1.0 0.8 0.6 0.4 0.2 0.0 LP - 300 + Cisplatin/Paclitaxel Placebo + Cisplatin/Paclitaxel All females N = 114, HR = 0.579 (p value 0.0477) LP - 300 + Cisplatin/Paclitaxel Placebo + Cisplatin/Paclitaxel Survival probability 1.0 0.8 0.6 0.4 0.2 0.0 Survival months 0 10 20 30 Female never - smokers N = 66, HR = 0.367 (p value 0.0167) Survival months 0 10 20 30 1.0 0.8 0.6 0.4 0.2 0.0 LP - 300 + Cisplatin/Paclitaxel Placebo + Cisplatin/Paclitaxel Survival probability Female never - smokers showed the clearest statistically significant positive outcome among subgroups in the LP - 300 treatment arm in advanced adenocarcinoma patients in Phase III LP - 300 16

Nasdaq: LTRN 17 Proposed design for relaunching of Phase II clinical trial for LP - 300 in a targeted patient population Histology / demographic/ smoking history screening LP - 300 + standard of care (Dosing every 3 weeks and up to 8 treatment cycles) Efficacy Endpoints Never - smoker NSCLC Adenocarcinoma patients • Primary: Overall Survival • Secondary: Objective Response Rate/ Clinical Benefit Rate/ Progression - Free Survival/ Quality of Life 50 – 75 stratified patients • Non - Randomized • Masking: None (Open Label) • Primary Purpose: Treatment • Study arms: Single experimental arm Trial Design Collection of patient genomic and biomarker data for future stratification LP - 300

Nasdaq: LTRN 18 Lung Cancer in Never - Smokers (LCINS) – a hidden but rising disease • 7 th leading cause of death among patients with solid tumors • More frequent in women with ~2/3 of patients with no reported smoking history • Adenocarcinoma is the most common histology accounting for ~60% of non - smoking NSCLC patients • 20% to 25% of global lung cancer cases and deaths occur among never - smokers **Mutation frequency data compiled by Lantern Pharma from 6 studies • LP - 300 patent application for use in never - smoking NSCLC patients (potential protection until 2039) 9.5 19.5 1995 2013 % 13 28 2008 2014 % LP - 300 Incidence of NSCLC in non - smokers in the U.K.* Incidence of NSCLC in non - smokers in the USA* • Significant mutational difference in LCINS v. Smokers – esp. in EGFR, TP53, STK11 and KRAS** * Proli C et al., ASCO 2015; Pelosof L et al., ASCO 2015

Nasdaq: LTRN 19 LP - 184 for solid tumors and certain PTGR1 expressing cancers & ADC program Unique Features • Hydroxyurea Methylacylfulvene • Nanomolar potency across multiple solid tumor (pancreas, prostate, liver) and glioblastoma cell lines • Broad anti - tumor agent that counteracts multi - drug resistance and is independent of other mutations (p53, KEAP1) • Favorable in vitro and in vivo efficacy allowing improved therapeutic index and pharmacokinetics • Promising blood - brain - barrier (BBB) profile • Key payload for ADC Program • 6 new patent filings: 2 new applications on synthetic manufacturing of new molecular entities • Wet lab validated 16 gene signature leveraging NCI Cell Miner platform from our collaboration • Validated BBB permeability in both nuerospheres and wet - lab experiments • Q4 ’20 collaboration with Georgetown in prostate cancer • Q4 ‘20 collaboration with Johns Hopkins in GBM • Q3’ 20 collaboration with Fox Chase to advance targeted use in molecularly defined types of pancreatic cancer. • Q3 ’20 established manufacturing for phase 1 clinical trials in GBM and solid tumors. Current status LP - 184

Nasdaq: LTRN 20 LP - 184 treatment resulted in greater tumor regression in a mouse model with human cancer Source: Staake et al., Bioorganic & Medicinal Chemistry Letters (2016) 10 1 0.1 10 20 30 Time (days) Relative Tumor Weight No Drug LP - 100, 10 mg/kg LP - 184, 10 mg/kg LP - 184, 20 mg/kg Drugs administered i.p. 3x a week for 3 weeks Treatment of Mice Engrafted with Human MV522 Multi - drug Resistant Tumor Cells LP - 184

Nasdaq: LTRN 21 Proposed LP - 184 mechanism of action based on acylfulvene drugs 1. Potential synergistic drug combinations due to involvement w/ DNA repair pathway and supported by gene correlation studies 2. Approved drugs in certain drug classes have been identified to be synergistic with LP - 184 when used in combination for cancer treatment LP - 184 Active Metabolite Enzymatic Biotransformation Conversion of LP - 184 prodrug to active form by AOR ( alkenal /one oxidoreductase) activity of PTGR1 (Prostaglandin Reductase1) DNA Damage Induction Alkylation of DNA and adduct formation with processing of lesions exclusively by Transcription Coupled Nucleotide Excision Repair (TC - NER) pathway involving CHK1 and PARP among other members. LP - 184

Nasdaq: LTRN 22 Tumors with highest potential based on PTGR1 expression and gene signature activity Lung Prostate Kidney Colon Brain / CNS LP - 184: High Positive Pan Tumor Correlation with PTGR1 Expression 40 kDa sgRNA#1 #2 #3 sgCrtl Parental P ANC03.27+ dCas9-KRAB A 0 25 50 75 100 125 #1 #2 #3 C t rl Pa r en t al PTGR1 mRN A (qPCR), AU B 0 0 . 2 5 0 . 5 0 . 7 5 1 0 2 0 0 4 0 0 6 0 0 8 0 0 1 0 0 0 (-) LP 184 , nM s g C on t r o l s g P T G R 1 - 2 O M O M O O O H 5 , R h 2 ( O A c ) 4 O H 2 O O H H O I B X , D M S O M e M g C l , T H F , - 2 0 ° C N a B H 4 , M e O H + 2 H 2 O , 1 1 0 ° C 1 3 4 O O O O H O O H O O M O M 6 1 1 1 2 O H O C h i r a l r e s o l u t i o n 9 9 % 4 5 % K 2 C O 3 , M e O H O O H O H H O 1 ) D I B A L - H , C H 2 C l 2 , - 7 8 ° C 2 ) H 3 P O 4 / s i l i c a , E t O A c O H H O ( ± ) - 9 O H H O 9 A O H H O ( − ) - a c y l f u l v e n e ( 1 0 ) ( + ) - a c y l f u l v e n e ( 1 0 ) + 9 B + O O O H M O M C l 1 4 O H O ( − ) - L P - 1 8 4 N O H N H 2 O C H 2 O , H 2 S O 4 , a c e t o n e / H 2 O ( 1 : 1 ) O H O O H ( − ) - I r o f u l v e n ( 1 3 ) N H N H 2 O H O + O H 2 O O H ( + ) - I r o f u l v e n ( 1 3 ) + O H O ( + ) - L P - 1 8 4 N O H N H 2 O 6 0 % 8 3 % ( f r o m 4 ) 6 5 % 3 4 % T M S O T f , 2 , 6 - l u t i d i n e ; N H 4 F / A c O H 2 9 % 7 7 % 7 5 % 5 5 % 6 4 % (-) Diastereomer of N-hydroxy-N-(methylacylfulvene)urea 0 0 . 2 5 0 . 5 0 . 7 5 1 0 2 0 0 4 0 0 6 0 0 8 0 0 1 0 0 0 (+) LP 184 , nM s g C on t r o l s g P T G R 1 -2 O M O M O O O H 5 , R h 2 ( O A c ) 4 O H 2 O O H H O I B X , D M S O M e M g C l , T H F , - 2 0 ° C N a B H 4 , M e O H + 2 H 2 O , 1 1 0 ° C 1 3 4 O O O O H O O H O O M O M 6 1 1 1 2 O H O C h i r a l r e s o l u t i o n 9 9 % 4 5 % K 2 C O 3 , M e O H O O H O H H O 1 ) D I B A L - H , C H 2 C l 2 , - 7 8 ° C 2 ) H 3 P O 4 / s i l i c a , E t O A c O H H O ( ± ) - 9 O H H O 9 A O H H O ( − ) - a c y l f u l v e n e ( 1 0 ) ( + ) - a c y l f u l v e n e ( 1 0 ) + 9 B + O O O H M O M C l 1 4 O H O ( − ) - L P - 1 8 4 N O H N H 2 O C H 2 O , H 2 S O 4 , a c e t o n e / H 2 O ( 1 : 1 ) O H O O H ( − ) - I r o f u l v e n ( 1 3 ) N H N H 2 O H O + O H 2 O O H ( + ) - I r o f u l v e n ( 1 3 ) + O H O ( + ) - L P - 1 8 4 N O H N H 2 O 6 0 % 8 3 % ( f r o m 4 ) 6 5 % 3 4 % T M S O T f , 2 , 6 - l u t i d i n e ; N H 4 F / A c O H 2 9 % 7 7 % 7 5 % 5 5 % 6 4 % (+) Diastereomer of N-hydroxy-N-(methylacylfulvene)urea C D PTGR1 a - T ubulin V iabilit y , % V iabilit y , % CRISPR - mediated stable suppression of PTGR1 expression in pancreatic cancer cell line is sufficient to fully diminish LP - 184 activity

Nasdaq: LTRN 23 1 10 100 1,000 10,000 100,000 1,000,000 SNU387_Liver H2228_NSCLC H1944_NSCLC OV90_Ovary NIHOVCAR3_Ovary IC50 [ nM ] Cell Line ID_Cancer Type LP-184 Cisplatin Pemetrexed Nanomolar potency Micromolar potency LP - 184 shows a 10x – 3,800x increase in in vitro potency over approved chemotherapeutics in various solid tumors LP - 184 IC50 data from Lantern generated data, Cisplatin and Pemetrexed IC50s from GDSC database LP - 184

Nasdaq: LTRN 24 LP - 184 shows significant promise in improving patient outcomes in Glioblastoma (GBM) – a rare cancer with median survival of < 1 year 37.4 46.4 47.7 231 274000 513000 293000 129000 1 10 100 1,000 10,000 100,000 1,000,000 SF268 SF295 SNB75 U251 IC50 [ nM ] Comparative sensitivity of LP - 184 across GBM cell lines LP-184 TMZ The current standard of care for GBM consists of de - bulking surgery followed by combined treatments with fractionated ionizing radiation (IR) and the DNA alkylating agent temozolomide (TMZ) which less than 50% of patients respond to* LP - 184 500x – 13,000x increase in in - vitro potency over TMZ, (the current standard in GBM) Molecule BBB permeability probability score Developmental stage LP - 184 0.9694 Preclinical TMZ 0.9879 Approved Carmustine 0.9533 Approved Cilengitide 0.9362 Phase II LP - 184 has a favorable CNS drug profile – blood brain barrier (BBB) permeability Using admetSAR2 , a tool for evaluating chemical ADMET (absorption, distribution, metabolism, excretion - toxicity) properties Source: Genes & Disease, Volume 3, Issue 3, Sep. 2016 0 pp. 198 - 210

Nasdaq: LTRN 25 LP - 184 is highly effective in ex vivo PDX models of DNA Damage Repair Deficient (HRD+) solid tumors LP - 184 response in a representative pancreatic cancer model with PARP1, ATR* and BRIP1 mutations Patient was a non - responder to 5 - Fluorouracil/ Irinotecan/ Oxaliplatin combination Hoechst (all nuclei) CellTracker Green (live cells) p - γ H2A.X (DNA damage) EdU (S phase of cell cycle) 0.1% DMSO (negative control) 36 uM LP - 184 10% DMSO (positive control) 4 uM LP - 184 Post - treatment Day 5 Staining 10% DMSO (positive control) Post - treatment Day 5 Cell Viability Readout 0.1% DMSO (negative control) LP - 184 IC50 [ nM ] Dose response curve fit (R 2 ) Maximum inhibition (%) Olaparib IC50 [ nM ] 45 0.96 97 7900 *high impact mutation LP - 184

Nasdaq: LTRN 26 LP - 184 IC50 values in multiple ATRT cell lines suggest that it is able to potently kill these cancers LP - 184 shows in vitro potency in ATRT - an ultra - rare CNS cancer mostly occurring in children driven by SMARCB1 expression as predicted by RADR 1770 162 37.4 1 10 100 1000 CHLA-02 CHLA-05 CHLA-06 LP - 184 IC50 [nM] ATRT cell line Increased LP - 184 sensitivity (reported in terms of – log 10 IC 50 [M]) correlates with decreased SMARCB 1 transcript levels (reported in terms of log 2 microarray expression) among solid tumors (r = - 0 . 48 , p value 0 . 00028 )

Nasdaq: LTRN 27 Initial data from ADC Program Converted an antibody with no intrinsic biological activity to an ADC! One can treat even MDR refractory leukemias (whether T - cell, B - cell, myeloid or myeloma leukemias) LP - A18 has an LD50 of 7 nM versus IC50 2 - 7 nM for Adcetris ® or Kadcyla ® LP - A18 Adcetris ® Kadcyla ® LP - A18* v. other ADCs based on data submitted to FDA

Nasdaq: LTRN 28 RADR ® - A robust and scalable platform for accelerating the development of targeted cancer therapy, precision trials and Companion Dx Model Data Sets Data Sources AI Methods Being Deployed • > 1 Billion transcriptomic and drug sensitivity data points • >144 drug - tumor interactions • > 55,400 + real world patient data • Using automation and AI to grow data - sets • Public Sources such as Gene Expression Omnibus (GEO), Cancer Cell Line Encyclopedia (CCLE), Genomics of Drug Sensitivity in Cancer (GDSC), • Industry Data • Proprietary Data • Analytics: Integrated systems biology , statistical and descriptive analysis • Machine Learning: Supervised ML (Neural Network & Support Vector), variations in established ML algorithms: XGBoost Real World Applications • Robust precision medicine/drug development • Uncovering potential drug combinations • Predicting synergy with Immuno - oncology agents • Drug repositioning, revitalization & rescue • Companion Dx development Open Source & Published Data AI Data Curation & Normalization Machine Learning Frameworks Internally Generated Data Collaboration & Partner Data Output Secure Cloud Based Storage & Computing

Nasdaq: LTRN 29 RADR ® identifies genetic markers and signatures for precision oncology drug development, clinical response prediction and CDx enablement Output & Signature Development Process Platform Architecture Success in Blinded Predictions Oncology Patient Records & Response Information Drug - Tumor Interactions Data Points Collected, Normalized, & Integrated from Real World, Translational & Clinical Cancer Evidence 80% 55,400+ 144+ ~1,100,000,000+

Nasdaq: LTRN 30 Uses machine learning methods to train on datasets Parameter tuning and model development and evaluation Biomarker Pa nel or Gene Signature for a CDx Guidance for clinical trial design & studies Training Set Optimal model used on testing dataset Genetic D ata Drug S ensitivity Data Gene Sets Tuned and Optimized Predictive Response Model RADR ® Workflow Details Testing Set Cancer Patient Population Partial Responders Non Responders Responders Optimized Predictive Response Model

Nasdaq: LTRN 31 108 Issued Patents Our Intellectual Property Portfolio – Extensive and continually growing position of over 80 issued patents & patent applications across 14 patent families Methods of Use Composition of Matter Drug Sensitivity & Response Signatures using Biomarkers LP - 100 LP - 184 LP - 300 5 families 7 families 2 families • In - licensed • Internally developed • In - licensed • Internally developed • In - licensed 80+ Issued Patents

Nasdaq: LTRN 32 Studies & Collaborations With Top Tier Academic & Research Partners

Nasdaq: LTRN 33 Heavy investment & investor interest in A.I. driven drug development Company Investment Feb. 2020 IPO (NASDAQ: SDGR) $239+ M. total Latest 09/2020 Series D Mar. 2018 IPO (NASDAQ: BTAI) $123+ M. total Latest 08/2020 Series B Valuation* $6,100+ Million $232 M. raised at IPO $1,300+ Million $65 M. raised at IPO 3 subsequent rounds $1,000+ Million (estimate based on last round) ~$1,100 Million (pre - money based on last round) Pipeline Status *Source: Crunchbase , Pitchbook and Bloomberg * Valuations of public companies as of January 7, 2021 • Ph. 3 – Neuro • Ph. 2 – Immuno Oncology • 5 compounds in early discovery • All oncology, targeted small molecule • Partners w/ academic, pharma and agrochemical firms. • No captive pipeline $290+ M. total Latest 09/2019 private raise • Partners w/ academic and pharma • Tech and service provider $500+ Million (estimate based on last round) • Various therapeutic areas • 3 Ph 3, 1 Ph 2, 17 in PC/discovery Jun. 2020 IPO (NASDAQ: LTRN) $115+ Million $26 M. raised at IPO • Oncology Focus in 4 programs • Ph. 2 – Prostate, Ph. 2 - NSCLC • Pre - Clin. – Solid Tumors & GBM

Nasdaq: LTRN 34 Value Building Milestones & Inflection Points 2021 2022 x LP - 300 Phase 2 Clinical Trial Launch x Advancement of CNS Programs w/ LP - 184 (GBM & ATRT) x Data from key collaborations Fox Chase, Georgetown and Johns Hopkins x Finalize IND - Enabling studies for LP - 184 in select genomically defined tumors x Launch initial ADC indications in pre - clinical x RADR platform expected to reach over 3Bn datapoints Foundational Year Advance Platform Trial Launches Progress ADC Compounds Multiple Streams of Value Creation Launch Multiple Precision Trials Leverage Platform for Pharma Partners Secure Additional Compounds Readout for multiple trials x LP - 300 Phase 2 Interim Readout x Launch clinical trials for GBM and other LP - 184 Indications x Finalize IND - Enabling studies for ADC & Launch Phase 1 x Develop or In - license additional programs in targeted indications x Explore pharma and biotech partnerships/arrangements x RADR platform expected to reach over 10Bn datapoints

Nasdaq: LTRN 35 Cap Table LANTERN PHARMA INC. (LTRN) Common Shares Outstanding 6,217,577 Warrants (WAEP $3.13) Underwriter Warrants (Exercise Price at $18.75) 262,014 70,000 Options (Employees, Management and Directors) 820,608 Fully Diluted Shares Outstanding 7,370,199 • Management and Directors own ~51% of fully diluted shares outstanding. • Committed to creating enduring growth and value for LTRN shareholders. Cap Table as of September 30, 2020

Nasdaq: LTRN 36 Highly experienced in innovation for pharma, drug development & oncology Management Team Kishor Bhatia, Ph.D., FRC Path Chief Scientific Officer A highly skilled scientist, inventor, manager, and administrator with over thirty years of experience building research programs and teams to create innovative treatments for cancer. Dr. Bhatia has expertise in DNA repair mechanisms, including contributions to understanding UV damage repair, the cloning of the PARP gene and its expression and the contribution of p53 gene in resistance to therapy. Former: • Director AIDS Malignancy Program. Office of HIV and AIDS Malignancy, National Cancer Institute • Director, Cancer Children’s Cancer Research Center, KFSHR&C, Riyadh • Director, International Network for Cancer Treatment and Research, Brussels • 1st to clone PARP gene involved in DNA damage • Over 250 publications with global collaborators & researchers David Margrave, J.D. Chief Financial Officer • 20+ years of oncology focused management experience. • Former President and as Chief Administrative Officer, BioNumerik Pharmaceuticals • Expertise in biotech deal structuring, and corporate management • Chairman of the Texas Healthcare and Bioscience Institute • Chairman of the State of Texas Product Development & Small Business Incubator Board • Univ. of Texas and Stanford graduate Panna Sharma President & CEO • Former President & CEO at Cancer Genetics (Nasdaq: CGIX) • Led IPO, Private investment round and multiple global acquisitions • Led CGIX to five years on Deloitte Fast 500 • Founder & CEO TSG Partners (Life Sciences Investment Bank & Strategy Consulting) • Chief Strategy Officer, iXL (Nasdaq: IIXL) • Analyst & Consultant, BankofAmerica , Putnam Investments, Interactive Solutions Kerry Barnhart, Ph.D., V.P. of Clinical Development Accomplished drug development professional and executive specializing in designing and directing oncology clinical programs from novel and breakthrough discoveries Former: • SVP of Development - CerRx • President & CEO – Transmed Oncology • President & CEO – Bradmer Pharma • CSO, Aptamera • B.S., M.S. – University of Arizona • Ph.D. & Post Doctoral Studies – Cornell University Graduate School of Medicine, Memorial Sloan Kettering, Salk Institute & U.C. San Diego

Nasdaq: LTRN 37 Investment Highlights - Lantern Pharma has a unique, growing and validated foundation for the future of cancer therapy and patient care Focused on cancer drug market segments with clear clinical need , understood mechanisms, targeted patient populations that exceed 1 Million , and multi - billion USD in annual sales potential Proven and growing library of A.I. & machine - learning methodologies published at ASCO, AACR and used to generate novel IP & patents and accelerate discovery by potentially years Growing A.I. based platform with clear roadmap to 6+ Bn. datapoints focused exquisitely on cancer therapeutic development and companion Dx in a high growth, high demand $4 Bn market Active drug rescue process and in the clinic with 2 compounds and accelerating additional compounds and combinations to clinical trials …potentially saving tens of millions and years of development Experienced and innovative management team w/ 60+ years experience in cancer and a passion to change the cost and outcome for cancer patients by using A.I. and genomics – paradigm changing technologies A novel ADC platform with the potential to develop and out - license or partner ADC assets in early phases Multiple compounds in place with the potential for Orphan Disease Designation and LP - 184 to be submitted for ODD in pancreatic and GBM which can help accelerate development Industry leading collaborations with National Cancer Institute, Georgetown, Johns Hopkins & Fox Chase Cancer Center

Nasdaq: LTRN 38 Lantern Pharma Company Overview Thank you! January 11, 2021

Nasdaq: LTRN 39 Appendix Items • Global A.I. Healthcare and Drug Discovery Market • Mega Trends Shaping the Future of Cancer Therapy • Source of Irofulven , LP - 100 • Board of Directors – Biographical sketches • Select recent publications and posters

Nasdaq: LTRN 40 Drug discovery and development driven by A.I. is a rapidly growing market in response to fundamental shifts in the industry and a re - tooling of R&D 0 200 400 600 800 1000 1200 2016 2024 *Source: Biopharmatrend.com , PMLiVE, and Global Market Insights, Inc. ~$4B A.I. - driven Drug Discovery/ Development market in 2024 $760M $10B Images Sources: Lantern Pharma as featured in ZDNet & Fortune Global A.I. Healthcare Market*

Nasdaq: LTRN 41 Solving unmet needs and creating opportunities in personalizing cancer therapy by capitalizing on emerging technologies and industry trends 1. Increased access to validated genomic & biomarker data 2. Increased sharing and collaboration globally among research groups, industry consortiums and companies 3. Rapidly decreasing cost (and increasing quality) of sequencing and biomarker data and other health - monitoring data 4. Rapid evolution & implementation of A.I. and machine learning technologies 5. Availability of well tolerated and clinically active but failed or abandoned compounds 6. Economic pressure to reposition & res cue drug investments 7. Rising need to develop and manage combination and drug - resistance addressing therapies 8. Increasing use of precision medicine and genomics to identify, treat and manage patients Mega Trends Shaping Drug Development

Nasdaq: LTRN 42 Irofulven , LP - 100, is derived from the Jack O’Lantern mushroom LP - 100, Irofulven LP - 184 LP - 300 • DNA Damaging Agent • Derived from highly toxic substance found in Jack o’Lantern mushroom – Illudin S • Company name “Lantern” is also derived from this origin of the compound • LP - 100 is a highly potent semi - synthetic derivative of the active toxic compound found in this fungi • Novel DNA Damaging Agent - member of the acylfulvene prodrug class • Favorable in vitro and in vivo efficacy across multiple tumor types • Broad anti - tumor agent that counteracts multi - drug resistance • Nanomolar potency • A.I. generated, validated and published gene signature for solid tumors • Disulfide bond disrupting agent with cysteine modifying activity on select proteins (ALK) and modulator of protein function (EGFR, MET, ROS1) • Chemosensitizer for combination therapies by inactivating proteins modulating cell redox status and drug resistance (TRX, GRX, PRX) • Chemoprotectant activity that reduces toxicities associated with taxane / platin - based chemotherapies

Nasdaq: LTRN 43 Jeff Donald Keyser, Ph.D., J.D., MPA • Board Chairman • Founder of Renibus Therapeutics and ZSPharma Franklyn Prendergast, M.D., Ph.D. Emeritus • Board of Governors and Board of Trustees, Mayo Clinic • Professor and Director – Mayo Clinic Comprehensive Cancer Center • Emeritus Member of Eli - Lily Board of Directors • Board of Directors, Lantern Pharma, Cancer Genetics, and TGEN • Distinguished Alumnus Mayo Clinic Vijay Chandru , Ph.D. • Co - Founder, Chairman Scientific Advisory Board, Strand Life Sciences • Fellow Indian Academies of Sciences and Engineering • Technology Pioneer, World Economic Forum • Co - Founder, Yantri Labs and other AI Compnies • Research Professor: IISc, Purdue, MIT, UPenn, Stanford David Silberstein, Ph.D., MPH Former • Director, Astra Zeneca • Sr. Director, MedImmune • Asst. Professor of Medicine, Harvard Medical School • Currently Principal Investigator of an NCI funded clinical trial in patients with multiple brain metastases Leslie (Les) W. Kreis • Managing Partner & Co - Founder, BIOS Partners • Principal & Founder, Steelhead Capital Management • Co - Founder, Cowtown Angels • Vice President, HRK Investments Panna Sharma • President & CEO, Lantern Pharma Board of Directors

Nasdaq: LTRN 44 Select Other Publications & Posters https:// ascopubs.org / doi /abs/10.1200/JCO.2020.38.15_suppl.e21660 https:// cancerres.aacrjournals.org /content/79/13_Supplement/4789 https:// www.lanternpharma.com /wp - content/uploads/2020/06/AACR - 2020 - LP - NCI - poster - final - pdf - 1.pdf https:// www.lanternpharma.com /wp - content/uploads/2020/06/AACR - 2020 - LP - Reprocell - poster - final - pdf.pdf